Sanofi Healthcare India Pvt. Ltd. today announced that it has received marketing authorization for Dupixent® (dupilumab), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not